Journal article

Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis

Tariq Ahmad, Umesh Basavaraju, Catriona Basquill, Fiona L Cameron, Christos Christodoulou, Fraser Cummings, Nik S Ding, Adam S Fadra, Lucy Flanders, Daniel R Gaya, Ian Gooding, John Gordon, Kay Grieveson, Richard Harris, Ailsa Hart, Philip Hendy, Peter Irving, Emma L Johnston, Matthew Johnston, Nicholas A Kennedy Show all

ALIMENTARY PHARMACOLOGY & THERAPEUTICS | WILEY | Published : 2016

Abstract

BACKGROUND: Infliximab and adalimumab have established roles in inflammatory bowel disease (IBD) therapy. UK regulators mandate reassessment after 12 months' anti-TNF therapy for IBD, with consideration of treatment withdrawal. There is a need for more data to establish the relapse rates following treatment cessation. AIM: To establish outcomes following anti-TNF withdrawal for sustained remission using new data from a large UK cohort, and assimilation of all available literature for systematic review and meta-analysis. METHODS: A retrospective observational study was performed on 166 patients with IBD (146 with Crohn's disease (CD) and 20 with ulcerative colitis [UC) and IBD unclassified (I..

View full abstract

University of Melbourne Researchers

Grants

Awarded by Wellcome Trust


Awarded by Medical Research Council


Awarded by National Institute for Health Research


Awarded by Chief Scientist Office


Funding Acknowledgements

Nicholas Kennedy was funded by a Research Training Fellowship from the Wellcome Trust [097943]. He has received speaker fees from MSD, Takeda, Falk, Pharmacosmos and Actavis. Nik Ding has served on an advisory board and as a speaker for Abbvie and Falk. Christopher Lamb is funded by a research training fellowship from the Wellcome Trust (093885/Z/10/Z). He has served as a speaker and consultant for Genentech/Roche, a speaker for Takeda and has received research funding from Genentech/Roche. Charles Murray has served as a speaker, a consultant and an advisory board member for Abbvie, MSD, Falk and Shire. Miles Parkes has served on advisory boards for Abbvie and MSD and has received research funding from Abbvie. Dan Gaya has spoken/worked in an advisory capacity for MSD, Abbvie, Takeda, Vifor pharma and Ferring. James Lindsay has served as a speaker, a consultant and an advisory board member for Abbvie, Ferring, MSD, Takeda, Jansen, Pfizer, Actavis, Napp, Hospira, Shire and Tillott's and has received research funding from Hospira, MSD and Shire. John Gordon has served as a consultant and an advisory board member for MSD, Abbvie, Ferring and Tillott's. Jack Satsangi has received speaker fees from MSD and Takeda and research support from Abbvie. Ailsa Hart has served as a speaker, consultant and advisory board member for AbbVie, Atlantic, BMS, Janssen, MSD, Falk, Ferring, Hospira, Napp, Pfizer and Takeda, Sara McCartney has served as a speaker, a consultant and an advisory board member for MSD, Abbvie, Falk, Takeda, Actavis, Ferring and Janssen. Peter Irving has served as a speaker, a consultant and an advisory board member for Abbvie, MSD, Takeda, Genentech, Ferring, Falk, Shire, Topivert, Pharmacosmos, Tillott's, Actavis, Johnson and Johnson, Hospira and Vifor and has received research funding from MSD. Dr Charlie Lees has received research support from Abbvie and Shire, acted as a consultant to Abbvie, MSD, Hospira, Pharmacosmos, Takeda, Vifor Pharma and Dr Falk and received speaking fees and travel support from Abbvie, MSD, Takeda, Shire, Ferring, Hospira, Warner-Chilcott and Dr Falk. Ben Warner, Emma Johnston, Lucy Flanders, Phil Hendy, Richard Harris, Adam Fadra Catriona Basquill, Fiona Cameron, Ian Gooding, Steve Mann have no personal interests to declare.